Floatz logo

oav101

Spinal Muscular Atrophy

Novartis PharmaceuticalsPhase 4 / ApprovedActive
BBB
78/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
71/ 100
Competitive Position
89/ 100

Competitive context

21 Active assets in the Spinal Muscular Atrophy cohort.

Asset / SponsorPhaseRating
Nusinersen
Scholar Rock, Inc.
Phase 4A
NON-REPLICATING RECOMBINANT SELF-COMPLEMENTARY (SC) ADENO-ASSOCIATED VIRUS SEROTYPE 9 (AAV9) VECTOR CONTAINING THE CDNA OF THE SURVIVAL OF MOTOR NEURON 2 (SMN2) GENE UNDER THE CONTROL OF THE HYBRID CYTOMEGALOVIRUS (CMV) ENHANCER/CHICKEN BETA-ACTIN PROMOTER (CBA)
Novartis Pharmaceuticals
Phase 4A
Risdiplam
Scholar Rock, Inc.
Phase 4A
Srk-015
Scholar Rock, Inc.
Phase 3BB
Hydroxyurea
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase 2/3BB

View all 40 →

Same molecule, other indications

oav101 is also rated in:

spinal muscular atrophy, type IIDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →